Pharmacoepidemiology Webinar | Design and Methodological Aspects of Pharmacoepidemiological Study for Young Researchers
the chairs
1st Pharmacoepidemiology Webinar
Design and Methodological Aspects of Pharmacoepidemiological Study for Young Researchers
It is our great pleasure to welcome you to the webinar “Design and Methodological Aspects of Pharmacoepidemiological Study for Young Researchers”, organized by the Hellenic Society of Pharmacoepidemiology in collaboration with the MDPI journal Pharmacoepidemiology.
This event brings together distinguished experts from across Europe and the United States to share practical insights and current perspectives on study design, methodological challenges, and analytical approaches in pharmacoepidemiology. Our aim is to support young researchers and early‑career scientists in developing rigorous, high‑quality research that can meaningfully contribute to public health and clinical decision-making.
We are honored to host a panel of renowned speakers who will cover a wide range of topics—from federated real‑world evidence and comparator selection to drug–drug interactions and approaches for addressing unmeasured confounding, including in vaccine safety research.
Their combined expertise will provide valuable learning opportunities for all attendees.
We hope this webinar will foster scientific exchange, encourage thoughtful discussion, and inspire the next generation of pharmacoepidemiologists. Thank you for joining us, and we wish you an engaging and informative session.
Date: 09 February 2026
Time: 3:00 pm CET | 09:00 am EST
Webinar ID: 860 7709 2738
Webinar Secretariat: journal.webinar@mdpi.com
Meet the Event Chairs
Meet Our Speakers
Prof. Dr. Björn Wettermark
Department of Pharmacy, University of Uppsala, Sweden;
Björn Wettermark, M.Sc.Pharm, PhD is professor of pharmacoepidemiology at Uppsala university, Sweden and visiting professor at Vilnius university, Lithuania. His research focus on drug utilization as a tool in health policy including prescribing quality indicators, international comparisons of drug utilization, sustainable drug prescribing, evidence generation for new medicines and patient adherence to treatment. He has previously had various managerial positions in the health region of Stockholm as well as other commitments including membership in national and regional strategic groups on medicine management, scientific advisor to the Swedish Medical Products Agency and chair of the European Drug Utilization Research group (EuroDURG), the European chapter of the International Society for Pharmacoepidemiology
Prof. Daniel Prieto-Alhambra
Health Data Sciences (HDS), Translational Sciences, Botnar Research Centre, University of Oxford, Oxford, UK., Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands;
Professor Daniel Prieto-Alhambra (MD, MSc (Oxon), PhD) is a clinician scientist with over 15 years’ experience in pharmacoepidemiology and real-world evidence. He is Professor of Pharmacoepidemiology at the University of Oxford, leads the Health Data Sciences section at the Botnar Research Centre, and has been Deputy Director of the EMA-funded DARWIN EU® initiative since 2022, also leading the HDR UK Real World Evidence Pilot Network. His research focuses on the analysis of national and international routine health data to inform regulatory and HTA decision-making. He has published over 420 papers (h-index 78) and has extensive experience supervising PhD students and mentoring researchers from assistant to associate professor.
Dr. Antonios Douros
Institute of Clinical Pharmacology and Toxicology, Charité – Universitätsmedizin Berlin, Berlin, Germany;
Dr. Douros is an Associate Professor at the Institute of Clinical Pharmacology and Toxicology at Charité – Universitätsmedizin Berlin. He received his Medical Degree in 2009 and his Doctorate Degree (Dr. med.) in 2012, and was trained in Clinical Pharmacology from 2012 to 2016 at Charité. He then completed a post-doctoral fellowship in Pharmacoepidemiology from 2016 to 2018 at the Department of Epidemiology, Biostatistics and Occupational Health at McGill University. From 2019 to 2023, he worked as an Assistant Professor at the McGill Department of Medicine and as an Investigator at the Lady Davis Institute for Medical Research at the Jewish General Hospital in Montreal. In 2023, he joined the Charité Institute of Clinical Pharmacology and Toxicology as an Associate Professor.
Dr. Douros's research focuses on the effectiveness and safety of commonly prescribed medications in vulnerable populations, including patients with chronic liver disease, older adults, and patients subjected to polypharmacy and at risk of drug-drug interactions. Given the underrepresentation of such populations in randomized trials, his research program provides much needed information regarding the benefit-risk profile of drugs. His research is supported by the German Research Foundation (Heisenberg Program 2023-present).
Dr. Farzin Khosrow-Khavar
Rutgers Center for Pharmacoepidemiology and Treatment Science at the Institute for Health, Health Care Policy and Aging Research, New Brunswick, New Jersey, United States;
Farzin Khosrow-Khavar, PhD, is an Assistant Professor of Epidemiology at the Rutgers School of Public Health and a core faculty member of the Center for Pharmacoepidemiology and Treatment Science (PETS) at the Rutgers Institute for Health. His research focuses on cancer pharmacoepidemiology, with an emphasis on the utilization and comparative effectiveness and safety of cancer therapies. His work leverages large linked electronic health records data sources such as SEER-Medicare and Veterans Affairs data to inform clinical and regulatory decision-making.
Dr. Sophie Bots
Division of Pharmacoepidemiology and Clinical Pharmacology , Utrecht Institute for Pharmaceutical Sciences, Utrecht University, the Netherlands;
Sophie is an Assistant Professor in Pharmacoepidemiology Methods. She has a background in Epidemiology and has experience with using regular care data for research from her PhD on sex differences in the safety and efficacy of cardiovascular medication. Her work focusses on the methodological challenges surrounding the use of real world data for research in the topic areas of safety of COVID-19 vaccinations and sex differences in de safety and dosage of cardiovascular medication.
In this section, you will find the recordings of this webinar to watch, re-watch and share with your colleagues!
The Hellenic Society of Pharmacoepidemiology (ELEFEP) in collaboration with MDPI organized the 1st webinar entitled: "Design and methodological aspects of a pharmacoepidemiological study for young researchers". Significant pharmacoepidemiologists from leading institutions in Europe and USA participated giving the inspiration to young researchers in pharmacoepidemiological research. The presentations and the discussion focused on relevant data access initiatives and methodological issues, which highlighted both challenges and opportunities for future work both in terms of setting up relevant infrastructures while also emphasizing the need for multidisciplinary collaboration (data scientistis, engineers, pharmacists etc.).
"Exploring Herbal Medicine: Applying Epidemiology Principles"
Edited by Dr. Christos Kontogiorgis